Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Asymchem Laboratories Tianjin Co EV-to-EBIT?
Asymchem Laboratories Tianjin CoASLTY +9.40%71 EV-to-EBIT is 27.96 as of Aug. 25, 2026, which is 22% below its 10-year median of 36.02. GuruFocus rates ASLTY with a GF Score™ of 71/100 and a GF Value™ of $4.91 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 376 Biotechnology companies, Asymchem Laboratories Tianjin Co ranks worse than 78.19% on this metric.
Asymchem Laboratories Tianjin Co (OTCPK:ASLTY) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Asymchem Laboratories Tianjin Co's Enterprise Value for the quarter that ended in Jun. 2026 was $3,612 Mil.
Asymchem Laboratories Tianjin Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $170 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asymchem Laboratories Tianjin Co EV-to-EBIT Related Terms
Asymchem Laboratories Tianjin Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Asymchem Laboratories Tianjin Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Asymchem Laboratories Tianjin Co EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Asymchem Laboratories Tianjin Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Asymchem Laboratories Tianjin Co's EV-to-EBIT falls into.
Asymchem Laboratories Tianjin Co's current Enterprise Value is $4,767 Mil.
Asymchem Laboratories Tianjin Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $170 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Asymchem Laboratories Tianjin Co (ASLTY) has a EV-to-EBIT of 27.96 as of Aug. 25, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Asymchem Laboratories Tianjin Co and its competitors. This is 22% below median its historical median of 36.02. Over the past decade, Asymchem Laboratories Tianjin Co's EV-to-EBIT has ranged from 7.26 to 201.70. According to the industry distribution chart, Asymchem Laboratories Tianjin Co ranks #294 out of 376 companies in the Biotechnology industry, placing it in the top 78.2%.
Is Asymchem Laboratories Tianjin Co's EV-to-EBIT too high?
Asymchem Laboratories Tianjin Co's current EV-to-EBIT of 27.96 is 22% below median its 10-year median of 36.02. Over the past 10 years, this metric has ranged from a low of 7.26 to a high of 201.70. The Biotechnology industry median EV-to-EBIT is 16.28. Asymchem Laboratories Tianjin Co's value of 27.96 is 71.8% above this industry median. Based on the distribution chart, Asymchem Laboratories Tianjin Co ranks #294 out of 376 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Asymchem Laboratories Tianjin Co has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Asymchem Laboratories Tianjin Co's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Asymchem Laboratories Tianjin Co ranks #294 out of 376 companies for EV-to-EBIT. This places Asymchem Laboratories Tianjin Co in the lower half of its industry. The industry median EV-to-EBIT is 16.28. Asymchem Laboratories Tianjin Co's value of 27.96 is 71.8% above this benchmark. Historically, Asymchem Laboratories Tianjin Co's own EV-to-EBIT has ranged from 7.26 to 201.70 over the past decade. While the company's 10-year median is 36.02 vs. the industry median of 16.28, Asymchem Laboratories Tianjin Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.28, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Asymchem Laboratories Tianjin Co's current EV-to-EBIT of 27.96 is 71.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Asymchem Laboratories Tianjin Co and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Asymchem Laboratories Tianjin Co's current EV-to-EBIT is 27.96, which is 22% below median its own 10-year median of 36.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Asymchem Laboratories Tianjin Co stock overvalued right now?
Based on GuruFocus' analysis, Asymchem Laboratories Tianjin Co (ASLTY) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.91, compared to a current price of $8.15 — trading 66% above its estimated fair value. The current EV-to-EBIT is 27.96, which is 22% below median its 10-year median of 36.02 and 71.8% above the Biotechnology industry median of 16.28. Asymchem Laboratories Tianjin Co's overall GF Score™ is 71/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Asymchem Laboratories Tianjin Co (ASLTY), the current EV-to-EBIT is 27.96 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Asymchem Laboratories Tianjin Co (ASLTY) Overvalued in 2026?
Based on GuruFocus' analysis, Asymchem Laboratories Tianjin Co stock appears to be overvalued.
The current stock price of $8.15 is trading 66% above its estimated GF Value™ of $4.91.
GuruFocus considers Asymchem Laboratories Tianjin Co to be Significantly Overvalued.
Key valuation signals for ASLTY:
EV-to-EBIT: 27.96 (22% below median its 10-year median of 36.02)
GF Value™: $4.91 vs. price of $8.15 (66% above fair value)
Industry Position: 71.8% above the Biotechnology median (#294 of 376)
No single metric tells the full story. See the ASLTY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Asymchem Laboratories Tianjin Co Ltd is a China-based company, a technology-driven provider of Contract Development and manufacturing organization solutions throughout the drug development and manufacturing process. The group provides clinical-stage CDMO solutions, commercial-stage CDMO solutions, and emerging services. Its operations relate to contract development and manufacturing, which focus on innovation and commercial application of pharmaceutical technology. It has geographic areas in the Chinese Mainland and Overseas.
71GF Score
Get the complete analysis for ASLTY
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASLTY has been successfully added to your 
